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Abstract
We examined whether the timing of the C-peptide response during an oral glucose tolerance test 
(OGTT) in relatives of patients with type 1 diabetes (T1D) is predictive of disease onset. We 
examined baseline 2-h OGTTs from 670 relatives participating in the Diabetes Prevention Trial-
Type 1 (age: 13.8 ± 9.6 years; body mass index z score: 0.3 ± 1.1; 56% male) using univariate 
regression models. T1D risk increased with lower early C-peptide responses (30–0 min) (χ2 = 
28.8, P < 0.001), and higher late C-peptide responses (120–60 min) (χ2 = 23.3, P < 0.001). When 
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both responses were included in a proportional hazards model, they remained independently and 
oppositely associated with T1D, with a stronger overall association for the combined model than 
either response alone (χ2 = 41.1; P < 0.001). Using receiver operating characteristic curve 
analysis, the combined early and late C-peptide response was more accurately predictive of T1D 
than area under the curve C-peptide (P = 0.005). Our findings demonstrate that lower early and 
higher late C-peptide responses serve as indicators of increased T1D risk.
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1 | INTRODUCTION
Previous studies suggest that partitioning C-peptide responses during a 2-h oral glucose 
tolerance test (OGTT) provides important information for assessing the natural history of the 
metabolic progression to type 1 diabetes (T1D) among autoantibody-positive (Ab+) relatives 
of individuals with the disease. Longitudinal analyses of Ab+ relatives of people with T1D 
showed that overall 2-h C-peptide measures [such as area under the curve (AUC) C-peptide] 
from OGTTs decrease gradually until 6 months before the diagnosis of T1D, followed by a 
marked decline.1 A subsequent analysis suggested that partitioning C-peptide responses 
according to time intervals provides more insight into the natural history of C-peptide loss, 
with early C-peptide responses (30–0 min C-peptide difference) decreasing, and later C-
peptide responses (sum of each of the differences of the 30-min C-peptide value from the 
60-, 90-and 120-min values) increasing within 2 years of diagnosis.2 However, it remains 
unknown to what extent this pattern of C-peptide responsiveness at baseline is predictive of 
T1D. Therefore, we examined whether partitioning the timing of the C-peptide response to 
an oral glucose load at a baseline exam is more predictive of the time to a diagnosis of T1D 
compared with the AUC C-peptide. In addition, we investigated the basis for the late 
response.
2 | MATERIALS AND METHODS
We analysed data from relatives of individuals with T1D (aged 1–45 years) who participated 
in the Diabetes Prevention Trial-Type 1 (DPT-1) with complete 2-h OGTT data. The DPT-1 
study has been previously described in detail.3 Briefly, participants were monitored with 2-h 
OGTTs every 6 months for the diagnosis of diabetes. Glucose and C-peptide levels were 
measured fasting and every 30 min. American Diabetes Association criteria for the diagnosis 
of diabetes were used for the interpretation of OGTTs.4 If an OGTT was in the diabetic 
range, a confirmatory OGTT was performed (unless otherwise clinically contraindicated). 
The date of diagnosis was based on the first OGTT results. A diagnosis could also be made 
according to the clinical presentation.
The early C-peptide response was defined as the 30–0 min C-peptide values (nmol/L). To 
avoid overlap in the 30-min C-peptide time point previously used for the definition of the 
later C-peptide response, we used the 120–60 min C-peptide as a measure of the late 
response. The AUC was calculated using the trapezoidal rule with the mean values of AUC 
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(/120 min) being presented. Plasma C-peptide levels were measured by radioimmunoassay, 
as has been previously described.1 Proportional hazards regression, with and without 
covariate adjustments, was used to assess associations. For certain analyses the early and late 
C-peptide responses were combined to form a single variable using their coefficients from a 
proportional hazards model that included both variables.
Combined = − − 0.6225 × early response + 0.6163 × late response
The hazard ratio (HR) for each response is based on a 1 nmol/L difference, with a ratio of <1 
indicative of lower risk and >1 indicative of greater risk. Receiver operating characteristic 
curves (ROC) were assessed according to time of follow-up with proportional hazards 
regression models. Pearson correlation was also utilized.
The data analysed or generated during the study are available on request from the authors.
3 | RESULTS
Baseline 2-h OGTTs from 670 DPT-1 participants [mean ± SD age:13.8 ± 9.6 years; body 
mass index (BMI) z-score: 0.3 ± 1.1; 56% male] were analysed. In total, 241 progressed to 
T1D. The mean duration of follow-up was 3.8 ± 1.7 years.
Table 1 includes univariate proportional hazards regression models for the early C-peptide 
response, late C-peptide response and AUC C-peptide. The risk for a clinical T1D diagnosis 
was related significantly and inversely to the early C-peptide response (P < 0.0001 for HR). 
In contrast, another univariate regression model showed that the risk for T1D was 
significantly and positively related to the 120–60 min C-peptide difference (P < 0.0001 for 
HR). (Because of the differing directions of association, a 1 nmol/L increase in the early C-
peptide response was associated with a near halving of the HR, while a 1 nmol/L increase in 
the late C-peptide response was associated with an approximate doubling of the HR.) Each 
C-peptide response (i.e., early and late responses) was at least as associated with T1D 
development [χ2 = 28.8 (P <0.0001) and χ2 = 23.3 (P <0.0001), respectively] as the AUC 
C-peptide (χ2 = 20.4), which is a standard overall C-peptide response measure. As also 
shown in Table 1, all of the associations persisted with adjustments for age and BMI z-score.
The early and late C-peptide responses were independently and oppositely associated with 
T1D in a model, including both variables: inverse for the early C-peptide response [HR: 0.54 
(0.41–0.70); P < 0.0001] and positive for the late C-peptide response [HR: 1.85(1.35–2.53); 
P < 0.0001]. These associations persisted (P < 0.0001) for both with adjustments for age and 
BMI z-score. In addition, the overall association was stronger in the combined model 
(unadjusted χ2 = 41.1, P <0.0001). The association was further improved with the inclusion 
of age and BMI z-score in the model (χ2 = 67.6, P <0.0001). Table S1 (see Supporting 
Information) shows the mean ± SD C-peptide values at each OGTT time point.
Table 2 shows that the values of prediction accuracy indicators were similar between the 
AUC C-peptide and each of the early and late C-peptide responses. However, the values 
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tended to improve for a combined variable that included both the early and late C-peptide 
responses (based upon proportional hazards regression coefficients).
We performed an ROC analysis to assess further the accuracy of prediction when OGTT C-
peptide responses are partitioned into early and late responses. Table S2 (see Supporting 
Information) provides areas under the ROC for the C-peptide measures. The areas under the 
ROC were significantly higher for the 30–0 min C-peptide (P = 0.039), and for the 30–0 min 
C-peptide combined with the 120–60 min C-peptide (P = 0.005), than for the AUC C-
peptide.
To explain why a high late C-peptide response is predictive of greater T1D risk, we 
examined the association between the sum of glucose levels from 60 to 120 min and the 
120–60 min C-peptide response. The 120–60 min C-peptide response was positively 
associated with the sum of glucose levels from 60 to 120 min (r = 0.42, P <0.0001) (Figure 
S1; see Supporting Information). Moreover, there was a negative association between the 
120–60 min C-peptide and 30–0 min C-peptide (r = −0.29, P <0.0001) (Figure S2; see 
Supporting Information). When we also assessed the association between the early C-
peptide response and the glucose sum from 60 to 120 min, a negative association (r = −0.23, 
P <0.0001) was observed.
As the oral and parenteral insulin modalities could have influenced the findings in this study, 
we tested for interactions between treatment with insulin and the C-peptide measures. There 
were no significant interactions.
4 | DISCUSSION
The development of T1D was predicted by low early and high late C-peptide responses at 
baseline OGTTs in Ab+ relatives of individuals with T1D who were initially non-diabetic. 
The 30–0 min C-peptide difference and the 120–60 min C-peptide difference were each at 
least as predictive as the AUC C-peptide, and their prediction improved when they were 
included in combination. This was evident in both the regression and the ROC analyses. 
These findings are consistent with the changes in those responses during the progression to 
T1D in longitudinal studies.2
The practical value of using the combined early and late C-peptide responses (the higher the 
value, the greater the risk) versus using the standard AUC C-peptide measure (the lower the 
value, the greater the risk) is evident from the following example. For the combined variable, 
the 5-year T1D risk estimate was 68% for the highest risk quartile, while the estimate for the 
lowest risk quartile was 31%. For the AUC C-peptide the 5-year estimate for the highest risk 
quartile was 60%, whereas the estimate for the lowest risk quartile was 36% (Table S3; see 
Supporting Information). The wider separation between the highest risk and lowest risk 
quartiles of the combined variable suggests that it is a better indicator of the risk for T1D 
than the AUC C-peptide. This is supported by the greater log-rank χ2 for the combined 
variable evident in Table S3.
In assessing the metabolic effect of timing of C-peptide peaks, we observed that a lower 
early C-peptide response was associated with higher glucose levels during the second hour 
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of the OGTT and that the latter was associated with a higher late C-peptide response. This 
suggests that the greater T1D risk associated with the late C-peptide response is a function 
of a deficient early C-peptide response, resulting in higher late glucose levels and a 
compensatory higher late C-peptide response. Differences in changes of early and late C-
peptide response phases during progression are consistent with the longitudinal studies,1,2 
and with studies of impaired glucose tolerance and type 2 diabetes.5–7
The findings from partitioning the C-peptide response into early and late phases have several 
implications. Clinically, an appreciation of the different phases of the C-peptide response to 
an oral glucose challenge could potentially provide a more targeted approach for 
intervention and prevention therapies, as well as provide more physiological treatment 
approaches that further mimic normal timed insulin secretion of individuals at the onset of 
T1D. From a research perspective, partitioning should offer more insights than overall 
measures of the C-peptide response, such as the AUC C-peptide, for assessing β-cell 
function deterioration during the progression to T1D. Moreover, partitioning the C-peptide 
response provides additional predictive value of the disorder compared with the standard 
AUC C-peptide measure.
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